Min Yonghua, Li Xiaofeng, Chen Huafei, Xu Yumei, Lan Gang
Yonghua Min, Department of Chest Disease Center, Zhejiang Rongjun Hospital, 309 Shuangyuan Road, Jiaxing, Zhejiang Province 314000, P.R. China.
Xiaofeng Li, Department of Chest Disease Center, Zhejiang Rongjun Hospital, 309 Shuangyuan Road, Jiaxing, Zhejiang Province 314000, P.R. China.
Pak J Med Sci. 2024 Jan-Feb;40(3Part-II):534-543. doi: 10.12669/pjms.40.3.8397.
BACKGROUND & OBJECTIVE: Previous studies have suggested that the modified Glasgow Prognostic Score (mGPS) could be a potential biomarker for lung cancer (LC). However, the association between mGPS and overall survival (OS) or progression-free survival (PFS) in lung cancer patients remains unclear. The purpose of our study was to investigate possible correlation between mGPS and OS or PFS in LC patients.
An extensive search of PubMed, Cochrane Library, EMbase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Trip Database, Worldwide Science, and Google Scholar databases was done for relevant articles, published prior to May 30, 2021, that report correlation between mGPS and OS or PFS in LC patients. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were used as the main parameters for evaluation.
A total of 28 studies involving 9,748 lung cancer patients were analysed. The pooled analysis revealed that elevated mGPS (≥ 0) was associated with poor OS (HR=1.54; 95% CI, 1.32-1.77) and PFS (HR=1.49; 95% CI, 1.17-1.82). Furthermore, a significant correlation between mGPS (1 or 2) and OS was observed. However, no significant correlation was found between mGPS (1 or 2) and PFS. Subgroup analysis based on ethnicity demonstrated that mGPS ≥ 0 was associated with worse OS compared to mGPS=0 in both Asian (HR=1.46; 95% CI, 1.04-1.89; p<0.05) and Caucasian (HR=1.64; 95% CI, 1.35-1.94; p<0.05) cohorts of LC patients.
Our results demonstrate that positive mGPS is associated with poor survival results. Therefore, mGPS may be used as a biomarker for predicting prognosis in LC patients.
既往研究表明，改良格拉斯哥预后评分（mGPS）可能是肺癌（LC）的潜在生物标志物。然而，mGPS与肺癌患者总生存期（OS）或无进展生存期（PFS）之间的关联仍不明确。本研究旨在探讨LC患者中mGPS与OS或PFS之间的可能相关性。
对PubMed、Cochrane图书馆、EMbase、护理学与健康相关文献累积索引（CINAHL）、Trip数据库、全球科学数据库和谷歌学术数据库进行广泛检索，查找2021年5月30日前发表的报告mGPS与LC患者OS或PFS相关性的相关文章。采用合并风险比（HRs）和95%置信区间（CIs）作为主要评估参数。
共分析了涉及9748例肺癌患者的28项研究。汇总分析显示，mGPS升高（≥0）与较差的OS（HR=1.54；95%CI，1.32 - 1.77）和PFS（HR=1.49；95%CI，1.17 - 1.82）相关。此外，观察到mGPS（1或2）与OS之间存在显著相关性。然而，未发现mGPS（1或2）与PFS之间存在显著相关性。基于种族的亚组分析表明，在亚洲（HR=1.46；95%CI，1.04 - 1.89；p<0.05）和白种人（HR=1.64；95%CI，1.35 - 1.94；p<0.05）LC患者队列中，mGPS≥0与mGPS = 0相比，OS更差。
我们的结果表明，mGPS阳性与较差的生存结果相关。因此，mGPS可作为预测LC患者预后的生物标志物。
